New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 14, 2013
10:55 EDTNBS, NBS, ONVO, ONVO, LIFE, LIFE, GSK, GSK, CELG, CELG, BAX, BAX, STEM, STEM, OSIR, OSIR, BLUE, BLUE, SGMO, SGMO, FCSC, FCSC, PSTI, PSTI, MBLTY, MBLTY, ATHX, ATHX, BTX, BTXAlliance for Regenerative Medicine to hold a meeting
2013 Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 14-16 with webcasted presentations to begin on October 14 at 11 am; not all presentations may be webcasted. Webcast Link
News For NBS;ATHX;MBLTY;PSTI;FCSC;SGMO;BLUE;OSIR;STEM;BAX;CELG;GSK;LIFE;ONVO;BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 15, 2015
08:13 EDTBAXCoherus, Baxter announce amendment to etanercept biosimilar agreement
Coherus BioSciences (CHRS) and Baxter International (BAX) announced that they have amended certain financial terms of their collaboration agreement established in August 2013 regarding the development and commercialization of CHS-0214, an etanercept biosimilar product candidate, for Europe, Canada, Brazil, and certain other markets. Under the terms of the amended agreement, certain existing milestones and funding obligations have been revised, and the collaboration has been expanded to include select pre-commercialization activities. In aggregate, the revised milestone payments may exceed the previous Baxter funding obligations by approximately $12M. Additionally, Baxter has agreed to purchase Coherus common stock in a private placement transaction. All other contractual provisions remain materially unchanged.
06:07 EDTATHXStocks with implied volatility above IV index mean; ATHX WETF
Subscribe for More Information
April 14, 2015
07:38 EDTBAXBaxter removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
April 13, 2015
13:25 EDTFCSCEagle Pharmaceuticals appoints Fibrocell CEO to board of directors
Subscribe for More Information
09:34 EDTCELGActive equity options trading on open
Subscribe for More Information
09:13 EDTBLUEbluebird bio has a conference call hosted by JPMorgan
Subscribe for More Information
07:38 EDTATHXAthersys volatility elevated into Phase 2 ischemic stroke trial results
Subscribe for More Information
05:09 EDTCELGCelgene to purchase 14.35M shares of Mesoblast stock for A$3.82 per share
Subscribe for More Information
April 12, 2015
19:33 EDTCELGCelgene takes stake in Australia's Mesoblast, the Australian says
Subscribe for More Information
April 10, 2015
08:51 EDTBAXBaxter initiates voluntary recall of select lots of IV solutions
Subscribe for More Information
April 9, 2015
08:03 EDTOSIROsiris names Alla Danilkovitch as Chief Scientific Officer
Subscribe for More Information
07:40 EDTNBSNeoStem announces extension of study under grant from CIRM
NeoStem announced the extension of its study under a 2014 Early Translational grant from the California Institute of Regenerative Medicine, or CIRM, for research leading to the development of a treatment for retinal diseases, including macular degeneration and retinitis pigmentosa. Under the $4M grant made to the University of California, Irvine, NeoStem is entitled, through a subaward, to $1M of new funds adding to the original $0.5M awarded. The goals of the research are to generate three-dimensional retinal tissue, to investigate the ability of adult induced pluripotent stem cells to restore sight in rodent models of retinal degeneration and to make eventual preparations for clinical use of the tissue.
April 8, 2015
10:31 EDTATHXAthersys says Phase 2 ischemic stroke trial results to be presented at ESOC
Athersys announced that Dr. David Hess, a stroke specialist and Chairman of the Department of Neurology at the Medical College of Georgia Regents University, and the lead principal investigator in the study, will present the preliminary results from its Phase 2 clinical trial administering MultiStem for the treatment of ischemic stroke. The presentation will take place at the European Stroke Organization Conference 2015 on Sunday, April 19th starting at 8:50 am in Glasgow, Scotland, United Kingdom. Dr. Hess' presentation will be in the Boisdale Room of the Scottish Exhibition and Conference Centre in Glasgow, in the conference venue.Athersys' double-blind, placebo-controlled Phase 2 clinical trial is being conducted at leading stroke centers across the United States and in the United Kingdom to evaluate the safety and efficacy of its proprietary MultiStem cell therapy in adults who have suffered a severe ischemic stroke and are treated 24-48 hours following the stroke. Dr. Hess served as the lead clinician for the Phase 2 clinical trial, which also included clinical research teams from Oregon Health Sciences University, Houston Methodist Hospital, University of Pittsburgh Medical Center, Cleveland Clinic, Newcastle Upon Tyne and Stoke on Trent, among others. Trial enrollment was completed in December 2014 and this will be the first presentation of the unblinded results.
10:01 EDTONVOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
April 7, 2015
19:10 EDTONVOOn The Fly: After Hours Movers
Subscribe for More Information
16:08 EDTONVOOrganovo initiated with a Buy at Cantor
Subscribe for More Information
11:34 EDTONVOOrganovo jumps almost 8% after announcing pact with L'Oréal
Subscribe for More Information
10:38 EDTNBSNeoStem management to meet with Philadelphia Securities Association
Subscribe for More Information
07:24 EDTCELGCelgene Otezla has growing opportunity, says Bernstein
After interviewing small groups of New York City area dermatologists, Bernstein believes that Celgene's psoriasis,treatment, Otezla, has a growing opportunity, due to its oral dosing, convenience, and lack of immunosuppression. The firm quotes doctors as saying that the drug serves as a useful "stepping stone," for patients who might need more intensive therapy, but want to postpone or avoid biologic Bernstein keeps a $158 price target and Outperform rating on Celgene.
07:14 EDTGSKEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use